Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease

Neuronal ceroid lipofuscinoses (NCLs) are autosomal-recessive fatal neurodegenerative diseases that occur in children and young adults, with symptoms including ataxia, seizures and visual impairment. We report the discovery of cynomolgus macaques carrying the CLN2/TPP1 variant and our analysis of wh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental neurology 2023-05, Vol.363, p.114381-114381, Article 114381
Hauptverfasser: Munesue, Yoshiko, Ageyama, Naohide, Kimura, Nobuyuki, Takahashi, Ichiro, Nakayama, Shunya, Okabayashi, Sachi, Katakai, Yuko, Koie, Hiroshi, Yagami, Ken-ichi, Ishii, Kazuhiro, Tamaoka, Akira, Yasutomi, Yasuhiro, Shimozawa, Nobuhiro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 114381
container_issue
container_start_page 114381
container_title Experimental neurology
container_volume 363
creator Munesue, Yoshiko
Ageyama, Naohide
Kimura, Nobuyuki
Takahashi, Ichiro
Nakayama, Shunya
Okabayashi, Sachi
Katakai, Yuko
Koie, Hiroshi
Yagami, Ken-ichi
Ishii, Kazuhiro
Tamaoka, Akira
Yasutomi, Yasuhiro
Shimozawa, Nobuhiro
description Neuronal ceroid lipofuscinoses (NCLs) are autosomal-recessive fatal neurodegenerative diseases that occur in children and young adults, with symptoms including ataxia, seizures and visual impairment. We report the discovery of cynomolgus macaques carrying the CLN2/TPP1 variant and our analysis of whether the macaques could be a new non-human primate model for NCL type 2 (CLN2) disease. Three cynomolgus macaques presented progressive neuronal clinical symptoms such as limb tremors and gait disturbance after about 2 years of age. Morphological analyses using brain MRI at the endpoint of approximately 3 years of age revealed marked cerebellar and cerebral atrophy of the gray matter, with sulcus dilation, gyrus thinning, and ventricular enlargement. Histopathological analyses of three affected macaques revealed severe neuronal loss and degeneration in the cerebellar and cerebral cortices, accompanied by glial activation and/or changes in axonal morphology. Neurons observed throughout the central nervous system contained autofluorescent cytoplasmic pigments, which were identified as ceroid-lipofuscin based on staining properties, and the cerebral cortex examined by transmission electron microscopy had curvilinear profiles, the typical ultrastructural pattern of CLN2. These findings are commonly observed in all forms of NCL. DNA sequencing analysis identified a homozygous single-base deletion (c.42delC) of the CLN2/TPP1 gene, resulting in a frameshifted premature stop codon. Immunohistochemical analysis showed that tissue from the affected macaques lacked a detectable signal against TPP1, the product of the CLN2/TPP1 gene. Analysis for transmission of the CLN2/TPP1 mutated gene revealed that 47 (49.5%) and 48 (50.5%) of the 95 individuals genotyped in the CLN2-affected macaque family were heterozygous carriers and homozygous wild-type individuals, respectively. Thus, we identified cynomolgus macaques as a non-human primate model of CLN2 disease. The CLN2 macaques reported here could become a useful resource for research and the development of drugs and methods for treating CLN2 disease, which involves severe symptoms in humans. •Infantile cynomolgus macaques presented progressive neuronal disorders.•The affected macaques were diagnosed with a neuronal ceroid lipofuscinosis.•The macaques had a homozygous single-base deletion of the CLN2/TPP1 gene.•A novel cynomolgus macaque model of CLN2 disease was discovered.
doi_str_mv 10.1016/j.expneurol.2023.114381
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2787214631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014488623000651</els_id><sourcerecordid>2787214631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-ed20fe5a12b44940498fb59060a831d7a7de76205f116c98ed3ec860d89503003</originalsourceid><addsrcrecordid>eNqFkLFu2zAQhomgQeImeYWWYxc5dyRNUaNhtIkBA1namaDJU0BDElXSKuq3r1KnXjvd8v33332MfUZYIqB-PCzp9zjQlFO3FCDkElFJg1dsgdBAJZSED2wBgKpSxuhb9rGUAwA0StQ37FbqBg1ouWDbzWlIfepep8J7593PiXifAnU8tfxvweA67imnGHgXx9ROxcchlVj48TQSFzzEQq7QPbtuXVfo4X3esR_fvn7fPFe7l6ftZr2rvMT6WFEQ0NLKodgr1ShQjWn3qwY0OCMx1K4OVGsBqxZR-8ZQkOSNhmCaFUgAece-nPeOOc3XlqPtY_HUdW6gNBUralMLVFrijNZn1OdUSqbWjjn2Lp8sgn3zaA_24tG-ebRnj3Py03vJtO8pXHL_xM3A-gzQ_OqvSNnOWmjwFGImf7Qhxf-W_AGVk4gJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2787214631</pqid></control><display><type>article</type><title>Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Munesue, Yoshiko ; Ageyama, Naohide ; Kimura, Nobuyuki ; Takahashi, Ichiro ; Nakayama, Shunya ; Okabayashi, Sachi ; Katakai, Yuko ; Koie, Hiroshi ; Yagami, Ken-ichi ; Ishii, Kazuhiro ; Tamaoka, Akira ; Yasutomi, Yasuhiro ; Shimozawa, Nobuhiro</creator><creatorcontrib>Munesue, Yoshiko ; Ageyama, Naohide ; Kimura, Nobuyuki ; Takahashi, Ichiro ; Nakayama, Shunya ; Okabayashi, Sachi ; Katakai, Yuko ; Koie, Hiroshi ; Yagami, Ken-ichi ; Ishii, Kazuhiro ; Tamaoka, Akira ; Yasutomi, Yasuhiro ; Shimozawa, Nobuhiro</creatorcontrib><description>Neuronal ceroid lipofuscinoses (NCLs) are autosomal-recessive fatal neurodegenerative diseases that occur in children and young adults, with symptoms including ataxia, seizures and visual impairment. We report the discovery of cynomolgus macaques carrying the CLN2/TPP1 variant and our analysis of whether the macaques could be a new non-human primate model for NCL type 2 (CLN2) disease. Three cynomolgus macaques presented progressive neuronal clinical symptoms such as limb tremors and gait disturbance after about 2 years of age. Morphological analyses using brain MRI at the endpoint of approximately 3 years of age revealed marked cerebellar and cerebral atrophy of the gray matter, with sulcus dilation, gyrus thinning, and ventricular enlargement. Histopathological analyses of three affected macaques revealed severe neuronal loss and degeneration in the cerebellar and cerebral cortices, accompanied by glial activation and/or changes in axonal morphology. Neurons observed throughout the central nervous system contained autofluorescent cytoplasmic pigments, which were identified as ceroid-lipofuscin based on staining properties, and the cerebral cortex examined by transmission electron microscopy had curvilinear profiles, the typical ultrastructural pattern of CLN2. These findings are commonly observed in all forms of NCL. DNA sequencing analysis identified a homozygous single-base deletion (c.42delC) of the CLN2/TPP1 gene, resulting in a frameshifted premature stop codon. Immunohistochemical analysis showed that tissue from the affected macaques lacked a detectable signal against TPP1, the product of the CLN2/TPP1 gene. Analysis for transmission of the CLN2/TPP1 mutated gene revealed that 47 (49.5%) and 48 (50.5%) of the 95 individuals genotyped in the CLN2-affected macaque family were heterozygous carriers and homozygous wild-type individuals, respectively. Thus, we identified cynomolgus macaques as a non-human primate model of CLN2 disease. The CLN2 macaques reported here could become a useful resource for research and the development of drugs and methods for treating CLN2 disease, which involves severe symptoms in humans. •Infantile cynomolgus macaques presented progressive neuronal disorders.•The affected macaques were diagnosed with a neuronal ceroid lipofuscinosis.•The macaques had a homozygous single-base deletion of the CLN2/TPP1 gene.•A novel cynomolgus macaque model of CLN2 disease was discovered.</description><identifier>ISSN: 0014-4886</identifier><identifier>EISSN: 1090-2430</identifier><identifier>DOI: 10.1016/j.expneurol.2023.114381</identifier><identifier>PMID: 36918063</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aminopeptidases - chemistry ; Aminopeptidases - genetics ; Aminopeptidases - therapeutic use ; Animals ; Batten disease ; CLN2 disease ; cynomolgus macaque ; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - genetics ; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - therapeutic use ; Humans ; Lysosomal disease ; Macaca ; Neuronal ceroid lipofuscinosis ; Neuronal Ceroid-Lipofuscinoses - diagnostic imaging ; Neuronal Ceroid-Lipofuscinoses - genetics ; Neuronal Ceroid-Lipofuscinoses - pathology ; Non-human primate ; Serine Proteases - chemistry ; Serine Proteases - genetics ; Serine Proteases - therapeutic use ; Tripeptidyl-Peptidase 1</subject><ispartof>Experimental neurology, 2023-05, Vol.363, p.114381-114381, Article 114381</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c317t-ed20fe5a12b44940498fb59060a831d7a7de76205f116c98ed3ec860d89503003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0014488623000651$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36918063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Munesue, Yoshiko</creatorcontrib><creatorcontrib>Ageyama, Naohide</creatorcontrib><creatorcontrib>Kimura, Nobuyuki</creatorcontrib><creatorcontrib>Takahashi, Ichiro</creatorcontrib><creatorcontrib>Nakayama, Shunya</creatorcontrib><creatorcontrib>Okabayashi, Sachi</creatorcontrib><creatorcontrib>Katakai, Yuko</creatorcontrib><creatorcontrib>Koie, Hiroshi</creatorcontrib><creatorcontrib>Yagami, Ken-ichi</creatorcontrib><creatorcontrib>Ishii, Kazuhiro</creatorcontrib><creatorcontrib>Tamaoka, Akira</creatorcontrib><creatorcontrib>Yasutomi, Yasuhiro</creatorcontrib><creatorcontrib>Shimozawa, Nobuhiro</creatorcontrib><title>Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease</title><title>Experimental neurology</title><addtitle>Exp Neurol</addtitle><description>Neuronal ceroid lipofuscinoses (NCLs) are autosomal-recessive fatal neurodegenerative diseases that occur in children and young adults, with symptoms including ataxia, seizures and visual impairment. We report the discovery of cynomolgus macaques carrying the CLN2/TPP1 variant and our analysis of whether the macaques could be a new non-human primate model for NCL type 2 (CLN2) disease. Three cynomolgus macaques presented progressive neuronal clinical symptoms such as limb tremors and gait disturbance after about 2 years of age. Morphological analyses using brain MRI at the endpoint of approximately 3 years of age revealed marked cerebellar and cerebral atrophy of the gray matter, with sulcus dilation, gyrus thinning, and ventricular enlargement. Histopathological analyses of three affected macaques revealed severe neuronal loss and degeneration in the cerebellar and cerebral cortices, accompanied by glial activation and/or changes in axonal morphology. Neurons observed throughout the central nervous system contained autofluorescent cytoplasmic pigments, which were identified as ceroid-lipofuscin based on staining properties, and the cerebral cortex examined by transmission electron microscopy had curvilinear profiles, the typical ultrastructural pattern of CLN2. These findings are commonly observed in all forms of NCL. DNA sequencing analysis identified a homozygous single-base deletion (c.42delC) of the CLN2/TPP1 gene, resulting in a frameshifted premature stop codon. Immunohistochemical analysis showed that tissue from the affected macaques lacked a detectable signal against TPP1, the product of the CLN2/TPP1 gene. Analysis for transmission of the CLN2/TPP1 mutated gene revealed that 47 (49.5%) and 48 (50.5%) of the 95 individuals genotyped in the CLN2-affected macaque family were heterozygous carriers and homozygous wild-type individuals, respectively. Thus, we identified cynomolgus macaques as a non-human primate model of CLN2 disease. The CLN2 macaques reported here could become a useful resource for research and the development of drugs and methods for treating CLN2 disease, which involves severe symptoms in humans. •Infantile cynomolgus macaques presented progressive neuronal disorders.•The affected macaques were diagnosed with a neuronal ceroid lipofuscinosis.•The macaques had a homozygous single-base deletion of the CLN2/TPP1 gene.•A novel cynomolgus macaque model of CLN2 disease was discovered.</description><subject>Aminopeptidases - chemistry</subject><subject>Aminopeptidases - genetics</subject><subject>Aminopeptidases - therapeutic use</subject><subject>Animals</subject><subject>Batten disease</subject><subject>CLN2 disease</subject><subject>cynomolgus macaque</subject><subject>Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - genetics</subject><subject>Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - therapeutic use</subject><subject>Humans</subject><subject>Lysosomal disease</subject><subject>Macaca</subject><subject>Neuronal ceroid lipofuscinosis</subject><subject>Neuronal Ceroid-Lipofuscinoses - diagnostic imaging</subject><subject>Neuronal Ceroid-Lipofuscinoses - genetics</subject><subject>Neuronal Ceroid-Lipofuscinoses - pathology</subject><subject>Non-human primate</subject><subject>Serine Proteases - chemistry</subject><subject>Serine Proteases - genetics</subject><subject>Serine Proteases - therapeutic use</subject><subject>Tripeptidyl-Peptidase 1</subject><issn>0014-4886</issn><issn>1090-2430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLFu2zAQhomgQeImeYWWYxc5dyRNUaNhtIkBA1namaDJU0BDElXSKuq3r1KnXjvd8v33332MfUZYIqB-PCzp9zjQlFO3FCDkElFJg1dsgdBAJZSED2wBgKpSxuhb9rGUAwA0StQ37FbqBg1ouWDbzWlIfepep8J7593PiXifAnU8tfxvweA67imnGHgXx9ROxcchlVj48TQSFzzEQq7QPbtuXVfo4X3esR_fvn7fPFe7l6ftZr2rvMT6WFEQ0NLKodgr1ShQjWn3qwY0OCMx1K4OVGsBqxZR-8ZQkOSNhmCaFUgAece-nPeOOc3XlqPtY_HUdW6gNBUralMLVFrijNZn1OdUSqbWjjn2Lp8sgn3zaA_24tG-ebRnj3Py03vJtO8pXHL_xM3A-gzQ_OqvSNnOWmjwFGImf7Qhxf-W_AGVk4gJ</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Munesue, Yoshiko</creator><creator>Ageyama, Naohide</creator><creator>Kimura, Nobuyuki</creator><creator>Takahashi, Ichiro</creator><creator>Nakayama, Shunya</creator><creator>Okabayashi, Sachi</creator><creator>Katakai, Yuko</creator><creator>Koie, Hiroshi</creator><creator>Yagami, Ken-ichi</creator><creator>Ishii, Kazuhiro</creator><creator>Tamaoka, Akira</creator><creator>Yasutomi, Yasuhiro</creator><creator>Shimozawa, Nobuhiro</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202305</creationdate><title>Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease</title><author>Munesue, Yoshiko ; Ageyama, Naohide ; Kimura, Nobuyuki ; Takahashi, Ichiro ; Nakayama, Shunya ; Okabayashi, Sachi ; Katakai, Yuko ; Koie, Hiroshi ; Yagami, Ken-ichi ; Ishii, Kazuhiro ; Tamaoka, Akira ; Yasutomi, Yasuhiro ; Shimozawa, Nobuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-ed20fe5a12b44940498fb59060a831d7a7de76205f116c98ed3ec860d89503003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aminopeptidases - chemistry</topic><topic>Aminopeptidases - genetics</topic><topic>Aminopeptidases - therapeutic use</topic><topic>Animals</topic><topic>Batten disease</topic><topic>CLN2 disease</topic><topic>cynomolgus macaque</topic><topic>Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - genetics</topic><topic>Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - therapeutic use</topic><topic>Humans</topic><topic>Lysosomal disease</topic><topic>Macaca</topic><topic>Neuronal ceroid lipofuscinosis</topic><topic>Neuronal Ceroid-Lipofuscinoses - diagnostic imaging</topic><topic>Neuronal Ceroid-Lipofuscinoses - genetics</topic><topic>Neuronal Ceroid-Lipofuscinoses - pathology</topic><topic>Non-human primate</topic><topic>Serine Proteases - chemistry</topic><topic>Serine Proteases - genetics</topic><topic>Serine Proteases - therapeutic use</topic><topic>Tripeptidyl-Peptidase 1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Munesue, Yoshiko</creatorcontrib><creatorcontrib>Ageyama, Naohide</creatorcontrib><creatorcontrib>Kimura, Nobuyuki</creatorcontrib><creatorcontrib>Takahashi, Ichiro</creatorcontrib><creatorcontrib>Nakayama, Shunya</creatorcontrib><creatorcontrib>Okabayashi, Sachi</creatorcontrib><creatorcontrib>Katakai, Yuko</creatorcontrib><creatorcontrib>Koie, Hiroshi</creatorcontrib><creatorcontrib>Yagami, Ken-ichi</creatorcontrib><creatorcontrib>Ishii, Kazuhiro</creatorcontrib><creatorcontrib>Tamaoka, Akira</creatorcontrib><creatorcontrib>Yasutomi, Yasuhiro</creatorcontrib><creatorcontrib>Shimozawa, Nobuhiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Munesue, Yoshiko</au><au>Ageyama, Naohide</au><au>Kimura, Nobuyuki</au><au>Takahashi, Ichiro</au><au>Nakayama, Shunya</au><au>Okabayashi, Sachi</au><au>Katakai, Yuko</au><au>Koie, Hiroshi</au><au>Yagami, Ken-ichi</au><au>Ishii, Kazuhiro</au><au>Tamaoka, Akira</au><au>Yasutomi, Yasuhiro</au><au>Shimozawa, Nobuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease</atitle><jtitle>Experimental neurology</jtitle><addtitle>Exp Neurol</addtitle><date>2023-05</date><risdate>2023</risdate><volume>363</volume><spage>114381</spage><epage>114381</epage><pages>114381-114381</pages><artnum>114381</artnum><issn>0014-4886</issn><eissn>1090-2430</eissn><abstract>Neuronal ceroid lipofuscinoses (NCLs) are autosomal-recessive fatal neurodegenerative diseases that occur in children and young adults, with symptoms including ataxia, seizures and visual impairment. We report the discovery of cynomolgus macaques carrying the CLN2/TPP1 variant and our analysis of whether the macaques could be a new non-human primate model for NCL type 2 (CLN2) disease. Three cynomolgus macaques presented progressive neuronal clinical symptoms such as limb tremors and gait disturbance after about 2 years of age. Morphological analyses using brain MRI at the endpoint of approximately 3 years of age revealed marked cerebellar and cerebral atrophy of the gray matter, with sulcus dilation, gyrus thinning, and ventricular enlargement. Histopathological analyses of three affected macaques revealed severe neuronal loss and degeneration in the cerebellar and cerebral cortices, accompanied by glial activation and/or changes in axonal morphology. Neurons observed throughout the central nervous system contained autofluorescent cytoplasmic pigments, which were identified as ceroid-lipofuscin based on staining properties, and the cerebral cortex examined by transmission electron microscopy had curvilinear profiles, the typical ultrastructural pattern of CLN2. These findings are commonly observed in all forms of NCL. DNA sequencing analysis identified a homozygous single-base deletion (c.42delC) of the CLN2/TPP1 gene, resulting in a frameshifted premature stop codon. Immunohistochemical analysis showed that tissue from the affected macaques lacked a detectable signal against TPP1, the product of the CLN2/TPP1 gene. Analysis for transmission of the CLN2/TPP1 mutated gene revealed that 47 (49.5%) and 48 (50.5%) of the 95 individuals genotyped in the CLN2-affected macaque family were heterozygous carriers and homozygous wild-type individuals, respectively. Thus, we identified cynomolgus macaques as a non-human primate model of CLN2 disease. The CLN2 macaques reported here could become a useful resource for research and the development of drugs and methods for treating CLN2 disease, which involves severe symptoms in humans. •Infantile cynomolgus macaques presented progressive neuronal disorders.•The affected macaques were diagnosed with a neuronal ceroid lipofuscinosis.•The macaques had a homozygous single-base deletion of the CLN2/TPP1 gene.•A novel cynomolgus macaque model of CLN2 disease was discovered.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36918063</pmid><doi>10.1016/j.expneurol.2023.114381</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-4886
ispartof Experimental neurology, 2023-05, Vol.363, p.114381-114381, Article 114381
issn 0014-4886
1090-2430
language eng
recordid cdi_proquest_miscellaneous_2787214631
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aminopeptidases - chemistry
Aminopeptidases - genetics
Aminopeptidases - therapeutic use
Animals
Batten disease
CLN2 disease
cynomolgus macaque
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - genetics
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - therapeutic use
Humans
Lysosomal disease
Macaca
Neuronal ceroid lipofuscinosis
Neuronal Ceroid-Lipofuscinoses - diagnostic imaging
Neuronal Ceroid-Lipofuscinoses - genetics
Neuronal Ceroid-Lipofuscinoses - pathology
Non-human primate
Serine Proteases - chemistry
Serine Proteases - genetics
Serine Proteases - therapeutic use
Tripeptidyl-Peptidase 1
title Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T18%3A15%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cynomolgus%20macaque%20model%20of%20neuronal%20ceroid%20lipofuscinosis%20type%202%20disease&rft.jtitle=Experimental%20neurology&rft.au=Munesue,%20Yoshiko&rft.date=2023-05&rft.volume=363&rft.spage=114381&rft.epage=114381&rft.pages=114381-114381&rft.artnum=114381&rft.issn=0014-4886&rft.eissn=1090-2430&rft_id=info:doi/10.1016/j.expneurol.2023.114381&rft_dat=%3Cproquest_cross%3E2787214631%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2787214631&rft_id=info:pmid/36918063&rft_els_id=S0014488623000651&rfr_iscdi=true